Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134).-MedSci.cn - 梅斯（MedSci）

Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134).

Jensen, RE; Zheng, Y; Atkins, MB; Chmielowski, B; Tarhini, AA; Truong, TG; Davar, D; O'Rourke, MA; Curti, BD; Brell, JM; Kendra, KL; Ikeguchi, A; Lee, SJ; Potosky, AL; Wolchok, JD; Ribas, A; Kirkwood, JM; Wagner, LI; Cella, D

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务